Welcome to our dedicated page for Cti Biopharma news (Ticker: CTIC), a resource for investors and traders seeking the latest updates and insights on Cti Biopharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cti Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cti Biopharma's position in the market.
CTI BioPharma Corp. (CTIC) reported its Q3 2020 financial results, showing an operating loss of $11 million and no revenues for the quarter. This is compared to an operating loss of $9.7 million and revenues of $2.3 million in Q3 2019. The company announced the initiation of a rolling New Drug Application (NDA) for pacritinib targeting myelofibrosis patients with severe thrombocytopenia, expecting to complete the NDA submission in Q1 2021. Cash and equivalents stood at $57.4 million, enough to fund operations into Q4 2021.
CTI BioPharma Corp. (Nasdaq: CTIC) announced an oral presentation highlighting the development of pacritinib for graft versus host disease (GVHD) at the 62nd American Society of Hematology Annual Meeting, scheduled for December 5-8, 2020. The abstract titled Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention will be presented by Dr. Joseph Pidala during a session on December 6, 2020, at 10:00 a.m. PT. This presentation underscores CTIC's focus on innovative therapies targeting unmet medical needs in blood-related cancers.
CTI BioPharma Corp. (NASDAQ: CTIC) will announce its third quarter 2020 financial results on November 10, 2020, after the markets close. A conference call and webcast will follow at 4:30 p.m. ET to discuss results and provide a corporate update. The call can be accessed by phone at (877) 735-2860 (domestic) or (602) 563-8791 (international) with conference ID 5504037. A replay will be available for 30 days. CTI focuses on developing therapies for blood-related cancers, particularly myelofibrosis and COVID-19 treatment.
CTI BioPharma Corp. (Nasdaq: CTIC) has initiated a rolling New Drug Application (NDA) submission to the FDA for pacritinib, aimed at treating myelofibrosis patients with severe thrombocytopenia (platelet counts 50 x 10
CTI BioPharma Corp. (Nasdaq: CTIC) announced its plan to submit a New Drug Application (NDA) for pacritinib targeting myelofibrosis patients suffering from severe thrombocytopenia. Following a Pre-NDA meeting with the FDA, the NDA submission is set to begin in the coming weeks, aiming for completion in Q1 2021. This application will utilize data from completed Phase 3 trials (PERSIST-1, PERSIST-2) and the Phase 2 PAC203 trial. Currently, there are no approved treatments specifically for this patient group, indicating a significant unmet medical need.
CTI BioPharma Corp. (Nasdaq: CTIC) reported its financial results for Q2 2020, revealing an operating loss of $10.0 million, slightly improved from $11.0 million in Q2 2019. For the six months ended June 30, 2020, the operating loss was $21.9 million, up from $21.5 million in 2019. The company faced no revenue during this period, contrasting with $0.4 million and $1.1 million in the same periods of 2019. A net loss of $14.0 million was recorded for Q2 2020, equal to $(0.19) per share. Cash reserves remain robust at $70.1 million, forecasted to sustain operations through Q4 2021.